# DREAMM-3 (NCT04162210)

> Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04162210
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: GlaxoSmithKline
- Conditions: Multiple Myeloma
- Interventions: Belantamab mafodotin; Pom/dex (Pomalidomide plus low dose Dexamethasone)
- Enrollment: 325
- Primary outcome: Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG)

## Commentary we found

- X threads: 18
- YouTube: 6
- Podcasts: 5

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=dreamm-3-nct04162210

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04162210", "email": "<work email>"}; the inbox owner confirms by the emailed link.